Browsing by Author "Kurt Yüksel, Meltem"
Now showing items 1-7 of 7
-
CD5 as a prognostic marker in patients with diffuse large B-cell lymphoma: A multicenter study
Demirci, Ufuk; Kırkızlar, Hakkı Onur; Ümit, Elif Gülsüm; Gürsoy, Vildan; Pınar, İbrahim Ethem; Özkalemkaş, Fahir; Güven, Zeynep Tuğba; Kaynar, Leylagül; Keklik Karadağ, Fatma; Saydam, Güray; Ekinci, Ömer; Merter, Mustafa; Aras, Merih Reis; Albayrak, Murat; Karaman Gülsaran, Sedanur; Baş, Volkan; Balık Aydın, Berrin; Beköz, Hüseyin Saffet; Can, Ferda; Dilek, İmdat; Mehtap, Özgür; Öztürk, Erman; Çobanoğlu Şimşek, Bengü; Yıldırım, Murat; Aylı, Meltem; Ataş, Ünal; Salim, Ozan; Ayer, Mesut; Birtaş Ateşoğlu, Elif; Akay, Olga Meltem; Kurt Yüksel, Meltem; Paydaş, Semra; Korkmaz, Selçuk; Öz Puyan, Fulya; Demir, Ahmet Muzaffer (Springer Science and Business Media Deutschland GmbH, 2022)Diffuse large B-cell lymphoma (DLBCL) is the most common subtype of non-Hodgkin lymphoma (NHL) and comprises a heterogeneous group of disease. While classification of B-cell lymphomas has been evolving to include clonality ... -
Clinical characteristics and outcomes of COVID-19 in Turkish patients with hematological malignancies
Civriz Bozdağ, Sinem; Cengiz Seval, Güldane; Yönal Hindilerden, İpek; Hindilerden, Fehmi; Andıç, Neslihan; Baydar, Mustafa; Aydın Kanyar, Lale; Toprak, Selami Koçak; Göksoy, Hasan Sami; Balık Aydın, Berrin; Demirci, Ufuk; Can, Ferda; Özkocaman, Vildan; Gündüz, Eren; Güven, Zeynep Tuğba; Özkurt, Zübeyde Nur; Demircioğlu, Sinan; Beksaç, Meral; İnce, İdris; Yılmaz, Umut; Eroğlu Küçükdiler, Hilal; Abishov, Elgün; Yavuz, Boran; Ataş, Ünal; Mutlu, Yaşa Gül; Baş, Volkan; Özkalemkaş, Fahir; Üsküdar Teke, Hava; Gürsoy, Vildan; Çelik, Serhat; Çiftçiler, Rafiye; Yağcı, Münci; Topçuoğlu, Pervin; Çeneli, Özcan; Abbasov, Hamza; Selim, Cem; Ar, Muhlis Cem; Yücel, Orhan Kemal; Sadri, Sevil; Albayrak, Canan; Demir, Ahmet Muzaffer; Güler, Nil; Keklik, Muzaffer; Terzi, Hatice; Doğan, Ali; Yegin, Zeynep Arzu; Kurt Yüksel, Meltem; Sadri, Soğol; Yavaşoğlu, İrfan; Beköz, Hüseyin Saffet; Aksu, Tekin; Maral, Senem; Erol, Veysel; Kaynar, Leylagül; İlhan, Osman; Bolaman, Ali Zahit; Sevindik, Ömür Gökmen; Akyay, Arzu; Özcan, Muhit; Gürman, Günhan; Ünal, Şule; Yavuz, Yasemin; Diz Küçükkaya, Reyhan; Özsan, Güner Hayri (NLM (Medline), 2022)Objective: Patients with solid malignancies are more vulnerable to severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) infection than the healthy population. The outcome of SARS-CoV-2 infection in highly ... -
Ibrutinib as a promising treatment for pulmonary complications due to refractory chronic graft versus host disease
İlhan, Osman; Cengiz Seval, Güldane; Uzay, Ant; Kaya, Emin; Öztürk, Zübeyde Nur; Deveci, Burak; Yavaşoğlu, İrfan; Ural, Ali Uğur; Beköz, Hüseyin Saffet; Ayli, Meltem; Sevindik, Ömür Gökmen; Civriz Bozdağ, Sinem; Kurt Yüksel, Meltem; Gülbas, Zafer (Elsevier Science Inc, 2020)Introduction: Despite major improvements in allogeneic hematopoetic stem cell transplantation form matched related/ unrelated donor over last decades, chronic graft-versus-host disease (cGVHD) is still the leading cause ... -
An interim analysis of the Turkish Myeloma Registry among patients who have received up to two lines of therapy
Sevindik, Ömür Gökmen; Özkurt, Zübeyde Nur; Boğa, Can; Kalayoğlu Beşışık, Sevgi; İpek, Yıldız; Gedük, Ayfer; Harmandalı, Aybüke; Salihoğlu, Ayşe; Haydaroğlu Şahin, Handan; Sönmez, Mehmet; Vural, Filiz; Akay, Olga Meltem; Kurt Yüksel, Meltem; Maral, Senem; Ekinci, Ömer; Kırkızlar, Hakkı Onur; Tekinalp, Atakan; Demir, Nazlı; Merter, Mustafa; Saydam, Güray; Alacacıoğlu, İnci; Yeğin, Zeynep Arzu; Kasar, Mutlu; Mastanzade, Metban; Özsan, Güner Hayri (CIG Media Group, 2021)Background To investigate the demographics and treatment details of the myeloma patients who were diagnosed and followed up in Turkey and received up to two lines of therapy. Methods Patients who were recorded on the ... -
An interim analysis of the Turkish myeloma registry among the patients who have received up to two lines of therapy
Sevindik, Ömür Gökmen; Özkurt, Zübeyde Nur; Boğa, Can; Kalayoğlu Beşışık, Sevgi; Yıldız, İpek; Gedük, Ayfer; Harmandali, Aybüke; Salihoğlu, Ayşe; Haydaroğlu Şahin, Handan; Sönmez, Mehmet; Vural, Filiz; Akay, Olga Meltem; Kurt Yüksel, Meltem; Maral, Senem; Ekinci, Ömer; Kırkızlar, Hakkı Onur; Tekinalp, Atakan; Demir, Nazlı; Merter, Mustafa; Saydam, Güray; Alacacıoğlu, İnci; Yeğin, Zeynep Arzu; Kaşar, Mutlu; Mastanzade, Metban; Özsan, Güner Hayri (American Society of Hematology, 2021)... -
Is the end close for the graft-versus-host disease that is a big problem following allogeneic hematopoetic stem cell transplantation?
İlhan, Osman; Cengiz Seval, Güldane; Özkurt, Zübeyde Nur; Ural, Ali Uğur; Aylı, Meltem; Sevindik, Ömür Gökmen; Civriz Bozdağ, Sinem; Kurt Yüksel, Meltem; Gülbaş, Zafer; Özcan, Muhit (American Society of Hematology, 2018)… -
Nivolumab for relapsed or refractory Hodgkin lymphoma: Real-life experience
Beköz, Hüseyin; Özbalak, Murat; Karadurmuş, Nuri; Paydaş, Semra; Türker, Alev; Toptaş, Tayfur; Fıratlı Tuğlular, Tülin; Altuntaş, Fevzi; Kızıl Çakar, Merih; Sönmez, Mehmet; Gülbaş, Zafer; Demir, Nazlı; Kaynar, Leylagül; Yıldırım, Rahşan; Karadoğan, İhsan; Arat, Mutlu; Kapucu, İrem; Alayvaz Aslan, Nevin; Özkocaman, Vildan; Turgut, Mehmet; Kurt Yüksel, Meltem; Özcan, Muhit; Kabukçu Hacıoğlu, Sibel; Barışta, İbrahim; Demirkaya, Metin; Saydam, Güray; Toprak, Selami Koçak; Yılmaz, Mehmet; Demirkol, Onur; Ferhanoğlu, Burhan (Springer, 2020)Classical Hodgkin lymphoma (cHL) is considered a curable disease; however, in approximately one-third of the responding patients, the disease relapses following completion of therapy. One of the drugs that have been approved ...
